217 related articles for article (PubMed ID: 32949229)
21. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
[TBL] [Abstract][Full Text] [Related]
22. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
[TBL] [Abstract][Full Text] [Related]
23. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
Nabizadeh F; Pirahesh K; Valizadeh P
J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
[TBL] [Abstract][Full Text] [Related]
24. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid.
Shahnawaz M; Tokuda T; Waragai M; Mendez N; Ishii R; Trenkwalder C; Mollenhauer B; Soto C
JAMA Neurol; 2017 Feb; 74(2):163-172. PubMed ID: 27918765
[TBL] [Abstract][Full Text] [Related]
25. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
26. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
28. Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).
Vanderstichele H; Demeyer L; Janelidze S; Coart E; Stoops E; Mauroo K; Herbst V; François C; Hansson O
Alzheimers Res Ther; 2017 Jun; 9(1):40. PubMed ID: 28587660
[TBL] [Abstract][Full Text] [Related]
29. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
Aging Clin Exp Res; 2023 Aug; 35(8):1741-1752. PubMed ID: 37264166
[TBL] [Abstract][Full Text] [Related]
30. CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.
Irwin DJ; Xie SX; Coughlin D; Nevler N; Akhtar RS; McMillan CT; Lee EB; Wolk DA; Weintraub D; Chen-Plotkin A; Duda JE; Spindler M; Siderowf A; Hurtig HI; Shaw LM; Grossman M; Trojanowski JQ
Neurology; 2018 Mar; 90(12):e1038-e1046. PubMed ID: 29467305
[TBL] [Abstract][Full Text] [Related]
31. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
32. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.
Llorens F; Schmitz M; Varges D; Kruse N; Gotzmann N; Gmitterová K; Mollenhauer B; Zerr I
J Neurol; 2016 Nov; 263(11):2271-2277. PubMed ID: 27544498
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
35. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
[TBL] [Abstract][Full Text] [Related]
36. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT
J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650
[TBL] [Abstract][Full Text] [Related]
37. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
38. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.
Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Boström F; Hansson O; Nielsen HM
PLoS One; 2013; 8(1):e53250. PubMed ID: 23308173
[TBL] [Abstract][Full Text] [Related]
39. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
40. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]